liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis
Univ Naples Federico II, Italy; Polyedra Res Fdn, Italy.
Univ Buenos Aires, Argentina.
Univ Buenos Aires, Argentina.
Polyedra Res Fdn, Italy.
Show others and affiliations
2021 (English)In: Journal of Affective Disorders, ISSN 0165-0327, E-ISSN 1573-2517, Vol. 280, p. 409-431Article, review/survey (Refereed) Published
Abstract [en]

Background: There are scarce and discrepant data about the prevalence and correlates of co-occurring eating disorders (EDs) among people with a primary diagnosis of bipolar disorder (BD), and vice-versa, compelling a systematic review and meta-analysis on the matter. Methods: MEDLINE/PsycINFO databases were systematically searched for original studies documenting BD reversible arrow ED comorbidity across the lifespan, from inception up until April 20th, 2020. Random-effects meta-analysis and meta-regression analyses were conducted, accounting for multiple moderators. Results: Thirty-six studies involved 15,084 primary BD patients. Eleven studies encompassed 15,146 people with primary EDs. Binge eating disorder (BED) occurred in 12.5% (95%C.I.=9.4-16.6%, I-2=93.48%) of BDs, while 9.1% (95%C.I.=3.3-22.6%) of BEDs endorsed BD. Bulimia Nervosa (BN) occurred in 7.4% (95%C.I.=6-10%) of people with BD, whereas 6.7% (95%C.I.=12-29.2%) of subjects with BN had a diagnosis of BD. Anorexia Nervosa (AN) occurred in 3.8% (95%C.I.=2-6%) of people with BDs; 2% (95%C.I.=1-2%) of BD patients had a diagnosis of AN. Overall, BD patients with EDs had higher odds of being female vs. non-ED controls. Several moderators yielded statistically significant differences both within- and between different types of BDs and EDs. Limitations: Scant longitudinal studies, especially across different EDs and pediatric samples. High heterogeneity despite subgroup comparisons. Limited discrimination of the quality of the evidence. Conclusions: The rates of BD reversible arrow ED comorbidity vary across different diagnostic groups, more than they do according to the "direction" of BD reversible arrow ED. Further primary studies should focus on the risks, chronology, clinical impact, and management of the onset of intertwined BD reversible arrow ED across different ages, promoting a continuum approach.

Place, publisher, year, edition, pages
ELSEVIER , 2021. Vol. 280, p. 409-431
Keywords [en]
Bipolar disorder; Anorexia nervosa; Bulimia nervosa; Binge eating disorder; Prevalence; Comorbidity; Review; Meta-analysis, Psychiatry, Mental health; Neuroscience
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:liu:diva-172924DOI: 10.1016/j.jad.2020.11.015ISI: 000600653500008PubMedID: 33227671OAI: oai:DiVA.org:liu-172924DiVA, id: diva2:1522779
Note

Funding Agencies|Health Education England (HEE) [ICA-CL-2017-03-001]; National Institute for Health Research (NIHR)National Institute for Health Research (NIHR) [ICA-CL-2017-03-001]; NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust; Medical Research CouncilMedical Research Council UK (MRC); Guys and St Thomas Charity (GSTT); COMPASS Pathways Limited; Brain and Behavior Research Foundation; Physicians Services Incorporated Foundation; Stanley Medical Research Institute; University of TorontoUniversity of Toronto; NHMRC Senior Principal Research FellowshipNational Health and Medical Research Council of Australia [1156072]; AB-Biotics; AbbottAbbott Laboratories; AllerganAllergan; Angelini; AstraZenecaAstraZeneca; Bristol-Myers SquibbBristol-Myers Squibb; Dainippon Sumitomo PharmaDainippon Sumitomo Pharma Co., Ltd.; Farmindustria; Ferrer; Forest Research Institute; Galenica; Gedeon Richter; Glaxo-Smith-KlineGlaxoSmithKline; JanssenJohnson & Johnson USAJanssen Biotech Inc; LundbeckLundbeck Corporation; OtsukaOtsuka Pharmaceutical; PfizerPfizer; RocheRoche Holding; Sage; Sanofi-AventisSanofi-Aventis; ServierServier; Shire; Sunovion; TakedaTakeda Pharmaceutical Company Ltd; Brain and Behaviour Foundation; Generalitat de Catalunya (PERIS); Spanish Ministry of Science, Innovation and Universities (CIBERSAM); EU Horizon 2020

Available from: 2021-01-26 Created: 2021-01-26 Last updated: 2021-01-26

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dragioti, Elena
By organisation
Division of Prevention, Rehabilitation and Community MedicineFaculty of Medicine and Health SciencesPain and Rehabilitation Center
In the same journal
Journal of Affective Disorders
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 64 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf